Jesús Florián

456 total citations
13 papers, 137 citations indexed

About

Jesús Florián is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Jesús Florián has authored 13 papers receiving a total of 137 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Cancer Research and 2 papers in Genetics. Recurrent topics in Jesús Florián's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Jesús Florián is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Jesús Florián collaborates with scholars based in Spain and United States. Jesús Florián's co-authors include Antonio Antón, Francisco S. N. Lobo, Laura García‐Estévez, José Fortes, José Manuel López-Vega, Ana Herrero, A. Pelegrí, Àngels Arcusa, Eva Carrasco and Lourdes Calvo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Jesús Florián

12 papers receiving 133 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jesús Florián Spain 5 128 74 18 17 12 13 137
C. Tosello Brazil 3 78 0.6× 42 0.6× 24 1.3× 11 0.6× 6 0.5× 10 96
E Colajori Italy 5 105 0.8× 53 0.7× 25 1.4× 17 1.0× 9 0.8× 6 130
Nawal Kassem United States 6 52 0.4× 57 0.8× 17 0.9× 7 0.4× 20 1.7× 14 115
Eugenia Ortega Spain 6 44 0.3× 36 0.5× 25 1.4× 10 0.6× 10 0.8× 9 114
CL Shapiro United States 5 85 0.7× 58 0.8× 30 1.7× 14 0.8× 8 0.7× 9 128
Kai‐Keen Shiu United Kingdom 3 45 0.4× 58 0.8× 9 0.5× 7 0.4× 26 2.2× 3 95
Katia Ventura United States 6 104 0.8× 63 0.9× 24 1.3× 11 0.6× 12 1.0× 9 139
Fernanda Mosele France 5 72 0.6× 79 1.1× 53 2.9× 5 0.3× 14 1.2× 8 131
Benjamin Sadacca France 6 65 0.5× 63 0.9× 30 1.7× 12 0.7× 24 2.0× 6 133
A. Martoni Italy 7 101 0.8× 26 0.4× 67 3.7× 8 0.5× 6 0.5× 23 153

Countries citing papers authored by Jesús Florián

Since Specialization
Citations

This map shows the geographic impact of Jesús Florián's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús Florián with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús Florián more than expected).

Fields of papers citing papers by Jesús Florián

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús Florián. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús Florián. The network helps show where Jesús Florián may publish in the future.

Co-authorship network of co-authors of Jesús Florián

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús Florián. A scholar is included among the top collaborators of Jesús Florián based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús Florián. Jesús Florián is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Garcı́a, Jacinto, Sònia Servitja, Ana Santaballa, et al.. (2017). Abstract P6-09-33: CASCADE study: Rapid survival decline per treatment line in metastatic breast cancer. Cancer Research. 77(4_Supplement). P6–9.
2.
Servitja, Sònia, Ana Santaballa, Jacinto Garcı́a, et al.. (2016). CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients. Annals of Oncology. 27. vi76–vi76. 3 indexed citations
3.
Zamora, Pilar, et al.. (2016). Abstract P3-07-39: CASCADE study: Treatment and clinical outcomes of metastatic breast cancer by tumor immunophenotypes. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations
4.
Antón, Antonio, Agustí Barnadas, Jesús Florián, et al.. (2011). Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study. Clinical & Translational Oncology. 13(4). 281–286. 3 indexed citations
5.
Bustos, Aurelia, F. Carabantes, Nieves Díaz, et al.. (2011). Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Current Medical Research and Opinion. 28(1). 57–67. 3 indexed citations
6.
Pelegrí, A., Lourdes Calvo, Antonio Antón, et al.. (2005). Docetaxel/Gemcitabine Administered Every Other Week as First-Line Treatment for Metastatic Breast Cancer: Final Results of a Phase II Trial. Clinical Breast Cancer. 6(5). 433–438. 21 indexed citations
7.
Más, Luís, et al.. (2005). Concurrent chemotherapy and radiotherapy for the treatment of cervix uterine cancer at experience in a general hospital. Journal of Clinical Oncology. 23(16_suppl). 5182–5182. 1 indexed citations
8.
Puértolas, Teresa, et al.. (2004). Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Journal of Clinical Oncology. 22(14_suppl). 751–751. 4 indexed citations
9.
Pelegrí, A., Lourdes Calvo, José Mayordomo, et al.. (2004). Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial. Seminars in Oncology. 31(2 Suppl 5). 20–24. 15 indexed citations
10.
García‐Estévez, Laura, Antonio Antón, Jesús Florián, et al.. (2003). Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.. PubMed. 9(2). 686–92. 61 indexed citations
11.
Virizuela, Juan Antonio, Jesús Florián, M. Lomas, et al.. (2003). Gemcitabine/Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines: Results of a Phase II Trial. Clinical Breast Cancer. 4(1). 46–50. 14 indexed citations
12.
Alba, Emilio, Nuria Ribelles, A. Antón, et al.. (2003). Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study. Breast Cancer Research and Treatment. 77(1). 1–8. 7 indexed citations
13.
Alonso, Vicente, Carmen Santander, Jesús Florián, et al.. (1996). Phase II Trial of Oral Tegafur and Folinic Acid with Mitoxantrone as First-Line Regimen in Patients with Metastatic Breast Cancer. Tumori Journal. 82(1). 61–64. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Tosello Breakdown of academic impact, for papers by E Colajori Breakdown of academic impact, for papers by Nawal Kassem Breakdown of academic impact, for papers by Eugenia Ortega Breakdown of academic impact, for papers by CL Shapiro Breakdown of academic impact, for papers by Kai‐Keen Shiu Breakdown of academic impact, for papers by Katia Ventura Breakdown of academic impact, for papers by Fernanda Mosele Breakdown of academic impact, for papers by Benjamin Sadacca Breakdown of academic impact, for papers by A. Martoni
Rankless by CCL
2026